Dyne Therapeutics logo

Dyne Therapeutics

DYN | NASDAQ
Chart Builder DCF Calculator
$16.70
-$0.46 (-2.68%)
At close: Nov 16, 2026, 4:00 PM ET
$16.75
+$0.05 (+0.30%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.68%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
15.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1011/1021 (Top 99%)

Key Statistics

Market Data

Market Cap $3.13B
1D Range
16.49 17.24
52W Range
14.25 26.78

Valuation (TTM)

PE -4.60
PB 3.36
EV/EBITDA -3.88

Valuation (NTM)

Forward PE N/A
Forward PEG -0.53
Price Target $36.00
Loading financial charts...

Profile

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is enginee...

Sector Healthcare
Industry Biotechnology
Employees 289
IPO Date Sep 17, 2020
Fiscal Year January - December

Latest News

Dyne Therapeutics to Participate in Upcoming Investor Conference

5 days ago · globenewswire.com

Dyne Therapeutics to Participate in Upcoming Investor Conference

12 days ago · globenewswire.com

Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

2 months ago · globenewswire.com

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

2 months ago · globenewswire.com

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics to Participate in Upcoming Investor Conferences

3 months ago · globenewswire.com

Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

4 months ago · globenewswire.com

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

4 months ago · globenewswire.com

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

4 months ago · globenewswire.com

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

4 months ago · globenewswire.com

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$36.50
Upside
+118.56%
Buy (8)
Hold (2)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.